Geert Leroux-Roels

Summary

Affiliation: Ghent University
Country: Belgium

Publications

  1. ncbi Development of prophylactic and therapeutic vaccines against hepatitis C virus
    Geert Leroux-Roels
    Centre for Vaccinology, Ghent University and Hospital, De Pintelaan 185, B 900 Ghent, Belgium
    Expert Rev Vaccines 4:351-71. 2005
  2. ncbi A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults
    Isabel Leroux-Roels
    Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    J Infect Dis 206:1280-90. 2012
  3. ncbi H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses
    Philippe Moris
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    J Clin Immunol 31:443-54. 2011
  4. ncbi Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine
    Isabel Leroux-Roels
    Centre for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    PLoS ONE 3:e1665. 2008
  5. ncbi Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine
    Geert Leroux-Roels
    Center for Vaccinology, Ghent University and Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    Clin Vaccine Immunol 18:1510-8. 2011
  6. ncbi Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data
    Geert Leroux-Roels
    Ghent University and Hospital, Center for Vaccinology, Ghent, Belgium
    Expert Opin Biol Ther 9:1057-71. 2009
  7. ncbi HCV animal models: a journey of more than 30 years
    Philip Meuleman
    Center for Vaccinology, Ghent University and Hospital, Building A, 1st Floor, De Pintelaan 185, B 9000 Gent, Belgium E mail
    Viruses 1:222-40. 2009
  8. ncbi Unmet needs in modern vaccinology: adjuvants to improve the immune response
    Geert Leroux-Roels
    Centre for Vaccinology, Ghent University and Hospital, Belgium
    Vaccine 28:C25-36. 2010
  9. ncbi Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse
    Thomas Vanwolleghem
    Center for Vaccinology, Ghent University and Hospital, Gent, Belgium
    Gastroenterology 133:1144-55. 2007
  10. ncbi Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice
    Thomas Vanwolleghem
    Center for Vaccinology, Ghent University and Hospital, Gent, Belgium
    J Hepatol 53:468-76. 2010

Detail Information

Publications71

  1. ncbi Development of prophylactic and therapeutic vaccines against hepatitis C virus
    Geert Leroux-Roels
    Centre for Vaccinology, Ghent University and Hospital, De Pintelaan 185, B 900 Ghent, Belgium
    Expert Rev Vaccines 4:351-71. 2005
    ..Finally, the only studies of therapeutic vaccines performed in humans to date are considered...
  2. ncbi A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults
    Isabel Leroux-Roels
    Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    J Infect Dis 206:1280-90. 2012
    ..An adjuvanted recombinant varicella zoster virus (VZV) subunit vaccine is being developed for the prevention of herpes zoster and its complications...
  3. ncbi H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses
    Philippe Moris
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    J Clin Immunol 31:443-54. 2011
    ..We determined the effect of adjuvantation on antibody persistence and B- and T-cell-mediated immune responses...
  4. ncbi Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine
    Isabel Leroux-Roels
    Centre for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    PLoS ONE 3:e1665. 2008
    ..2 and 2.3 respectively)...
  5. ncbi Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine
    Geert Leroux-Roels
    Center for Vaccinology, Ghent University and Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    Clin Vaccine Immunol 18:1510-8. 2011
    ..In conclusion, coadministration of the HPV-16/18 AS04-adjuvanted vaccine did not affect the immunogenicity or safety of the hepatitis B vaccine administered in an accelerated schedule in young women...
  6. ncbi Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data
    Geert Leroux-Roels
    Ghent University and Hospital, Center for Vaccinology, Ghent, Belgium
    Expert Opin Biol Ther 9:1057-71. 2009
    ..Universal and timely administration of a prepandemic vaccine is considered to be one of the most effective measures to reduce the incidence of pandemic influenza infection and consequently its morbidity and mortality...
  7. ncbi HCV animal models: a journey of more than 30 years
    Philip Meuleman
    Center for Vaccinology, Ghent University and Hospital, Building A, 1st Floor, De Pintelaan 185, B 9000 Gent, Belgium E mail
    Viruses 1:222-40. 2009
    ..In the past decade, several alternative animal models have been created. In this review we review these novel animal models and their contribution to our current understanding of the biology of HCV...
  8. ncbi Unmet needs in modern vaccinology: adjuvants to improve the immune response
    Geert Leroux-Roels
    Centre for Vaccinology, Ghent University and Hospital, Belgium
    Vaccine 28:C25-36. 2010
    ..This review focuses on the adjuvants and adjuvant systems currently in use in vaccines, future applications, and the remaining challenges the field is facing...
  9. ncbi Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse
    Thomas Vanwolleghem
    Center for Vaccinology, Ghent University and Hospital, Gent, Belgium
    Gastroenterology 133:1144-55. 2007
    ....
  10. ncbi Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice
    Thomas Vanwolleghem
    Center for Vaccinology, Ghent University and Hospital, Gent, Belgium
    J Hepatol 53:468-76. 2010
    ..The human liver-uPA(+/+)-SCID mouse is currently the best small animal model available for viral hepatitis infection studies...
  11. ncbi Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, 89 Rue de 1 institut, B 1330 Rixensart, Belgium
    Vaccine 23:2591-601. 2005
    ..AS02A can be considered as a useful adjuvant that strongly enhances the cellular and humoral responses of subunit protein vaccines...
  12. ncbi Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus
    Philip Meuleman
    Center for Vaccinology, Ghent University and Hospital, Building A, First Floor, De Pintelaan 185, 9000 Ghent, Belgium
    J Virol 80:2797-807. 2006
    ..These lesions show much resemblance to the ones encountered in immunosuppressed chronic HBV patients. Our observations indicate that HBV may be directly cytopathic in conditions of severe immune suppression...
  13. ncbi LPS-binding protein and CD14-dependent attachment of hepatitis B surface antigen to monocytes is determined by the phospholipid moiety of the particles
    Peter Vanlandschoot
    Center for Vaccinology, Department of Clinical Biology, Microbiology and Immunology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    J Gen Virol 83:2279-89. 2002
    ..The possible implications of these observations for hepatitis B virus (HBV) infection and HBV vaccine efficiency are discussed...
  14. ncbi In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus
    Philip Meuleman
    Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    Hepatology 53:755-62. 2011
    ..However, the in vivo protective efficacy of cross-genotype neutralizing antibodies was less than predicted by cell culture experiments...
  15. ncbi Hepatitis B virus surface antigen suppresses the activation of monocytes through interaction with a serum protein and a monocyte-specific receptor
    Peter Vanlandschoot
    Center for Vaccinology, Department of Clinical Biology, Microbiology and Immunology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    J Gen Virol 83:1281-9. 2002
    ..These results suggest the existence of a monocyte-specific receptor, the engagement of which by HBsAg suppresses the activity of these cells...
  16. ncbi Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection
    Philip Meuleman
    Center for Vaccinology, Ghent University and Hospital, Building A, 1st Floor, De Pintelaan 185, B-9000 Ghent, Belgium
    Clin Chim Acta 366:156-62. 2006
    ..In addition we demonstrate that HBV and HCV infections have no direct influence on the production of sCD14 by human hepatocytes in this chimeric model...
  17. ncbi Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems
    Isabel Leroux-Roels
    Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    Vaccine 28:7016-24. 2010
    ..All vaccine formulations exhibited acceptable safety and reactogenicity profiles. The demonstration of superior CD4(+) T-cell induction by AS01(B) provides important guidance for future HIV vaccine development...
  18. ncbi Production, characterization and in vitro testing of HBcAg-specific VHH intrabodies
    Benedikte Serruys
    Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    J Gen Virol 91:643-52. 2010
    ..These results suggest that HBcAg-specific VHHs targeted to the nucleus affect HBcAg and HBeAg expression and trafficking in HBV-transfected hepatocytes...
  19. ncbi Saccharomyces cerevisiae-derived HBsAg preparations differ in their attachment to monocytes, immune-suppressive potential, and T-cell immunogenicity
    Peter Vanlandschoot
    Center for Vaccinology, Department of Clinical Biology, Microbiology and Immunology, Ghent University Hospital, Ghent, Belgium
    J Med Virol 70:513-9. 2003
    ..Surprisingly, differences in phospholipid content that might explain these observations, were not detected...
  20. ncbi Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients
    Sophia Steyaert
    Ghent University and Hospital, Department of Clinical Chemistry, Microbiology and Immunology, Centre for Vaccinology, De Pintelaan 185, 9000 Ghent, Belgium
    Antiviral Res 75:129-38. 2007
    ....
  21. ncbi Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo
    Philip Meuleman
    Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    Hepatology 48:1761-8. 2008
    ....
  22. ncbi Soluble CD14 levels are increased and inversely correlated with the levels of hepatitis B surface antigen in chronic hepatitis B patients
    Sophia Steyaert
    Ghent University Hospital, Center for Vaccinology, Ghent, Belgium
    J Med Virol 71:188-94. 2003
    ..0217 and P = 0.0034, respectively). In chronic hepatitis B and C, sCD14 and C-reactive protein levels were higher in cirrhotic than in non-cirrhotic patients (P = 0.0072 and P = 0.0223, respectively)...
  23. ncbi An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers
    Eva Van Braeckel
    Center for Vaccinology, Ghent University and Hospital, Ghent Belgium
    Clin Infect Dis 52:522-31. 2011
    ..clinical trials registration: nct00434512...
  24. ncbi Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain
    Thomas Vanwolleghem
    Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    Hepatology 47:1846-55. 2008
    ..Both experimental systems will be useful tools to identify neutralizing antibodies for future clinical use...
  25. ncbi Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection
    Geert Leroux-Roels
    Center for Vaccinology, Gent University and Hospital, Gent, Belgium
    Hum Vaccin 1:61-5. 2005
    ..These data demonstrate that E1-specific immune responses can be induced in resolving HCV infections and that memory (B and T) cells can be restimulated with suboptimal doses of E1 antigen...
  26. ncbi Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study
    Isabel Leroux-Roels
    Center for Vaccinology, Ghent University and Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    Vaccine 28:849-57. 2010
    ..In contrast, priming without adjuvant appears to inhibit the response to subsequent vaccination with a heterologous strain. These findings should guide the development of vaccines to combat the present influenza A/H1N1 pandemic...
  27. ncbi Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment o
    Isabelle Desombere
    Department of Clinical Biology, Microbiology and Immunology, Center for Vaccinology, Ghent University and Hospital, De Pintelaan, 185, 9000 Ghent, Belgium
    J Clin Microbiol 43:2590-7. 2005
    ..This observation suggests that a TMA assay can lead to a more correct definition of the ETR response...
  28. ncbi Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial
    Isabel Leroux Roels
    Centre for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    Lancet 370:580-9. 2007
    ..We assessed the safety and immunogenicity of a recombinant H5N1 split-virion vaccine formulated with a proprietary adjuvant system and investigated whether it can induce cross-reactive immunity...
  29. ncbi Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice
    Benedikte Serruys
    Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    Hepatology 49:39-49. 2009
    ..To our knowledge, this is the first report of intrabody-mediated inhibition of viral secretion in mammals...
  30. ncbi Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults
    Isabel Leroux-Roels
    Center for Vaccinology, Ghent University and Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    Vaccine 27:6918-25. 2009
    ..H5N1 influenza vaccine is no less immunogenic in elderly adults than in younger adults and, due to a higher proportion non-naïve elderly, immunogenicity was higher in this latter group...
  31. ncbi Immunostimulatory potential of hepatitis B nucleocapsid preparations: lipopolysaccharide contamination should not be overlooked
    Peter Vanlandschoot
    Virus Host Interactions Unit, Center for Vaccinology, Department of Clinical Biology, Microbiology and Immunology, Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185, B 9000 Ghent, Belgium
    J Gen Virol 86:323-31. 2005
    ..This raises doubts on some of the underlying mechanisms that have been proposed to explain the unique immunogenicity of the HBV nucleocapsid...
  32. ncbi Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials
    Francois Roman
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Clin Vaccine Immunol 18:835-43. 2011
    ..Baseline A/H1N1/2009-specific CD4⁺ T-cell frequencies did not predict post-dose 1 antibody responses, but there was some correlation between post-dose 1 CD4⁺ T-cell frequencies and post-dose 2 antibody responses...
  33. ncbi The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV
    Philip Meuleman
    Center for Vaccinology, Ghent University and Hospital, Building A, 1st Floor, De Pintelaan 185, B 9000 Gent, Belgium
    Antiviral Res 80:231-8. 2008
    ....
  34. ncbi Vaccine-induced HIV seropositivity: a problem on the rise
    Eva Van Braeckel
    Center for Vaccinology, Ghent University and Hospital, De Pintelaan 185, B 9000 Ghent, Belgium
    J Clin Virol 50:334-7. 2011
    ..Vaccine-induced antibodies to envelope proteins frequently cause HIV seroconversion in uninfected recipients of HIV vaccine candidates and may thus have an impact on the vaccinee's ability to donate blood or acquire a life insurance policy...
  35. ncbi The nucleocapsid of the hepatitis B virus: a remarkable immunogenic structure
    Peter Vanlandschoot
    Department of Clinical Biology, Microbiology and Immunology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    Antiviral Res 60:67-74. 2003
    ..This leads to the generation of a dominant Th1 immunity phenotype and the secretion of high levels of IgM and IgG anti-nucleocapsid antibodies...
  36. ncbi Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen
    Isabelle Desombere
    Center for Vaccinology, Department of Clinical Biology, Microbiology and Immunology, Ghent University and Hospital, De Pintelaan 185, B 9000 Ghent, Belgium
    J Virol 80:3506-14. 2006
    ..In conclusion, our data show that partial delipidation of HBsAg strikingly increases the T-cell antigenicity of this unique viral antigen...
  37. ncbi Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, 1330 Rixensart, Belgium
    Vaccine 25:8585-97. 2007
    ....
  38. ncbi Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C
    Isabelle Desombere
    Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    J Med Virol 79:701-13. 2007
    ..In conclusion, in patients with chronic HCV infection, the decision to continue or stop treatment can be made after 1 week of treatment with (peg)-interferon alpha and ribavirin...
  39. ncbi The arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfate
    Peter Vanlandschoot
    Virus Host Interactions Unit, Center for Vaccinology, Department of Clinical Biology, Microbiology and Immunology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    J Gen Virol 86:75-84. 2005
    ..These observations demonstrated that the arginine-rich protamine-like regions of the core proteins are responsible for the attachment of nucleocapsids to glycosaminoglycans expressed on the plasma membranes of cells...
  40. ncbi The intraspleen huPBL NOD/SCID model to study the human HIV-specific antibody response selected in the course of natural infection
    Sophia Steyaert
    Ghent University and Hospital, Department of Clinical Chemistry, Microbiology and Immunology, Centre for Vaccinology, De Pintelaan 185, 9000 Ghent, Belgium
    J Immunol Methods 320:49-57. 2007
    ..We further conclude that the intraspleen huPBL NOD/SCID model is a small animal model useful for the analysis of the antibody response against HIV found in patients...
  41. ncbi A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo
    Philip Meuleman
    Center for Vaccinology, Ghent University and Hospital, Gent, Belgium
    Hepatology 55:364-72. 2012
    ..This strategy may be an efficacious way to prevent infection of allografts following liver transplantation in chronic HCV patients, and may even hold promise for the prevention of virus rebound during or following antiviral therapy...
  42. ncbi Recombinant HBsAg, an apoptotic-like lipoprotein, interferes with the LPS-induced activation of ERK-1/2 and JNK-1/2 in monocytes
    Peter Vanlandschoot
    Center for Vaccinology, Department of Clinical Biology, Microbiology, and Immunology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    Biochem Biophys Res Commun 297:486-91. 2002
    ..Addition of rHBsAg to LPS-stimulated cells reduces TNFalpha mRNA levels, but does not affect phosphorylation of p65 NF-kappaB and p38 MAP kinase. Instead, a reduced phosphorylation of ERK-1/2 and JNK-1/2 MAP kinases is observed...
  43. ncbi Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, 89 Rue de l Institut, 1330 Rixensart, Belgium
    Vaccine 26:1375-86. 2008
    ..g. malaria, HIV infection and tuberculosis, and for special target populations such as subjects with an impaired immune response, due to age or medical conditions...
  44. ncbi Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum
    Frédéric Clement
    Center for Vaccinology, Ghent University, Ghent, Belgium
    Malar J 11:384. 2012
    ..Vaccine immunogenicity is commonly evaluated by the determination of anti-CSP antibody levels using IgG-based assays, but no standard assay is available to allow comparison of the different vaccines...
  45. ncbi Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults
    Isabel Leroux-Roels
    Center for Vaccinology, Ghent University Hospital, De Pintelaan 185, B 9000 Ghent, Belgium
    Clin Vaccine Immunol 17:1763-71. 2010
    ..In conclusion, Mtb72F/AS02(A) is clinically well tolerated and is highly immunogenic in TB-naïve adults. The 10- and 40-μg Mtb72F/AS02(A) vaccines show comparable safety and immunogenicity profiles...
  46. ncbi Viral apoptotic mimicry: an immune evasion strategy developed by the hepatitis B virus?
    Peter Vanlandschoot
    Center for Vaccinology, Dept of Clinical Biology, Microbiology and Immunology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    Trends Immunol 24:144-7. 2003
    ..The possibility that the hepatitis B virus has evolved such a mechanism, termed "viral apoptotic-like mimicry", is presented here...
  47. ncbi Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults
    Isabel Leroux-Roels
    Center for Vaccinology, Ghent University and Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    Vaccine 26:6614-9. 2008
    ..Intradermal TIV induced non-inferior humoral immune responses against all three strains and superior responses against both A strains (H1N1, H3N2) compared with the control. Both vaccines were well tolerated...
  48. ncbi Detection and structural investigation of metabolites of stanozolol in human urine by liquid chromatography tandem mass spectrometry
    Oscar J Pozo
    DoCoLab, UGent, Department of Clinical Chemistry, Microbiology and Immunology, Technologiepark 30, B 9052 Zwijnaarde, Belgium
    Steroids 74:837-52. 2009
    ..Finally, a tentative structure for each detected metabolite has been proposed based on the product ion spectra measured with accurate masses using UPLC-QTOF MS...
  49. ncbi The uPA(+/+)-SCID mouse with humanized liver as a model for in vivo metabolism of 4-androstene-3,17-dione
    Leen Lootens
    Doping Control Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, 9052 Zwijnaarde, Belgium
    Drug Metab Dispos 37:2367-74. 2009
    ..The results for AD showed that humanized liver uPA-SCID mice can serve as an alternative model for in vivo metabolism studies in humans. In the future, this model could possibly be used for other steroids or pharmaceutical compounds...
  50. ncbi Steroid metabolism in chimeric mice with humanized liver
    Leen Lootens
    Department of Clinical Chemistry, Microbiology and Immunology, Doping control laboratory DoCoLab, Ghent University, Technologiepark 30, Zwijnaarde, Belgium
    Drug Test Anal 1:531-7. 2009
    ..It is hoped that, in future, this promising chimeric mouse model might assist the discovery of new and possible longer detectable metabolites of (designer) steroids...
  51. ncbi Griffithsin has antiviral activity against hepatitis C virus
    Philip Meuleman
    Institut Pasteur de Lille, Center for Infection and Immunity of Lille, 1 rue Calmette, 59021 Lille Cedex, France
    Antimicrob Agents Chemother 55:5159-67. 2011
    ..GRFT treatment of chronically infected HCV patients undergoing liver transplantation may be a suitable strategy to prevent infection of the liver allograft...
  52. ncbi Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera
    Philip Meuleman
    Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    Hepatology 41:847-56. 2005
    ..Supplementary material for this article can be found on the HEPATOLOGY website (http://www.interscience.wiley.com/jpages/0270-9139/suppmat/index.html)...
  53. ncbi Current status and progress of prepandemic and pandemic influenza vaccine development
    Isabel Leroux-Roels
    Center for Vaccinology, Ghent University and Hospital, De Pintelaan 185, 9000, Ghent, Belgium
    Expert Rev Vaccines 8:401-23. 2009
    ..A detailed overview is given of the most successful candidate vaccines developed by seven vaccine manufacturers...
  54. ncbi Randomized phase i: safety, immunogenicity and mucosal antiviral activity in young healthy women vaccinated with HIV-1 Gp41 P1 peptide on virosomes
    Geert Leroux-Roels
    Center for Vaccinology CEVAC, Ghent University Hospital, Ghent, Belgium
    PLoS ONE 8:e55438. 2013
    ..Vaccine-induced mucosal anti-gp41 antibodies toward conserved gp41 motifs were harboring HIV-1 transcytosis inhibition activity and may contribute to reduce sexually-transmitted HIV-1. TRIAL REGISTRATION: ClinicalTrials.gov NCT01084343...
  55. ncbi The Sin3a repressor complex is a master regulator of STAT transcriptional activity
    Laura Icardi
    Department of Medical Protein Research, Vlaams Instituut voor Biotechnologie, 9000 Ghent, Belgium
    Proc Natl Acad Sci U S A 109:12058-63. 2012
    ..The Sin3a complex therefore acts as a context-dependent ISGF3/STAT3 transcriptional switch...
  56. ncbi A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers
    Geert Leroux-Roels
    Center for Vaccinology, Ghent University and Hospital, De Pintelaan 185, B-9000 Ghent, Belgium
    Vaccine 22:3080-6. 2004
    ..A strong, specific cellular immune response towards E1 was elicited in all vaccine recipients, which included a clear Th1 type response in all but one of the subjects...
  57. ncbi Characterization of HLA DR13-restricted CD4(+) T cell epitopes of hepatitis B core antigen associated with self-limited, acute hepatitis B
    Tinghua Cao
    Center for Vaccinology, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium
    J Gen Virol 83:3023-33. 2002
    ..Of four T cell lines, two recognized P15 and two recognized P5. By peptide mapping, the minimal epitope of P15 was located to residues (147)TVVRRRGRSP(156)...
  58. ncbi Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant
    Isabelle Desombere
    Centre for Vaccinology, Ghent University Hospital, De Pintelaan 185 9000, Ghent, Belgium
    Vaccine 20:2597-602. 2002
    ..The HBsAg/AS04 vaccine was more reactogenic mainly because of an increased local reactogenicity. Both vaccines, especially HBsAg/AS04, are highly immunogenic and well tolerated by the study subjects...
  59. ncbi Expression, purification and characterization of full-length RNA-free hepatitis B core particles
    Katleen Broos
    Laboratory of Plant Physiology, Department of Biology, 171 Groenenborgerlaan, Building U, 6th Floor, CGB University of Antwerp, 2020 Antwerpen, Belgium
    Protein Expr Purif 54:30-7. 2007
    ..In this report, we detail a novel method for the synthesis and purification of full-length core particles essentially free of RNA from Escherichia coli...
  60. ncbi Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha
    Cosme Alvarado Esquivel
    Departamento de Inmunologia y Biologia Molecular, Instituto de Investigacion Cientifica, Departamento de Microbiologia, Facultad de Medicina, UJED
    Rev Invest Clin 54:41-50. 2002
    ....
  61. ncbi Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant
    Artur Kaul
    Department of Molecular Virology, University of Heidelberg, Im Neuenheimer Feld 345, 69120 Heidelberg, Germany
    J Virol 81:13168-79. 2007
    ..These results argue for some level of impaired fitness of this mutant in vivo...
  62. ncbi Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit
    Katleen Broos
    Laboratory of Plant Physiology, Department of Biology, University of Antwerp, Antwerp, Belgium
    Clin Vaccine Immunol 15:852-8. 2008
    ..These immunizations, in contrast, induced predominantly antibodies of the IgG1 isotype, indicative of a Th2 response. These data suggest that the HBc VLP can be an interesting carrier molecule in oral vaccine development...
  63. ncbi An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults
    Karin Levie
    Ecole de Santé Publique, Universite Catholique de Louvain, Brussels
    J Infect Dis 198:642-9. 2008
    ..To protect a naive global population against pandemic influenza, pandemic vaccines should be effective at low antigen doses, because of limited manufacturing capacity...
  64. ncbi Contamination of a recombinant hepatitis B virus nucleocapsid preparation with a human B-cell activator
    Peter Vanlandschoot
    J Virol 81:2535-6. 2007
  65. ncbi A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C
    Frederik Nevens
    Department of Hepatology, UZ Gasthuisberg, Belgium
    Hepatology 38:1289-96. 2003
    ..01). In conclusion, E1 therapeutic vaccination is well tolerated and the observed effects warrant further study...
  66. ncbi The role of heparan sulfate and TLR2 in cytokine induction by hepatitis B virus capsids
    Peter Vanlandschoot
    J Immunol 175:6253; author reply 6253-5. 2005
  67. ncbi Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses
    Catharina Hultgren
    Division of Clinical Virology, F68, Karolinska Institutet, Huddinge University Hospital, S-141 86 Huddinge, Sweden
    J Hepatol 40:971-8. 2004
    ..05), and a shorter viral half-life (P<0.05). CONCLUSIONS: The presence of an NS3-specific T cell response is related to the viral genotype and to a more rapid clearance of HCV RNA during antiviral therapy...
  68. ncbi Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity
    Joe Grove
    Division of Immunity and Infection, Institute for Biomedical Research, The Medical School, Birmingham University, Edgbaston B14 2TT, United Kingdom
    J Virol 81:3162-9. 2007
    ..Finally, anti-SR-BI antibodies inhibited the infectivity of cell culture- and plasma-derived J6/JFH, suggesting a critical role for SR-BI/II in HCV infection...
  69. ncbi Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
    Brett D Lindenbach
    Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 103:3805-9. 2006
    ..These results greatly extend the utility of the HCVcc genetic system to allow the complete in vitro and in vivo dissection of the HCV life cycle...
  70. ncbi Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine
    David I Bernstein
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA
    Clin Infect Dis 40:1271-81. 2005
    ....
  71. ncbi Features of the CD4+ T-cell response in liver and peripheral blood of hepatitis C virus-infected patients with persistently normal and abnormal alanine aminotransferase levels
    Miguel A Rico
    Institute of Hepatology, Hospital Pardo de Aravaca, Madrid, Spain
    J Hepatol 36:408-16. 2002
    ..However, these Th1 responses are detected more often in those patients with overt clinical and histological disease...